From Stock Story: 2025-02-19 16:22:32

Exact Sciences Corporation (NASDAQ:EXAS) reported Q4 CY2024 revenue of $713.4 million, surpassing analyst estimates by 1.6%. The company expects full-year revenue to reach $3.06 billion. Non-GAAP loss per share was better than expected at -$0.06. Despite a negative operating margin of 123%, the company’s revenue grew by 10.3% year-on-year. Exact Sciences has shown strong sales growth, with a 25.8% compounded annual growth rate over the last five years. Analysts forecast a 10.9% revenue growth over the next 12 months. The market reacted negatively to the results, with the stock trading down 1.9% after the report.

Founded in 1995, Exact Sciences Corporation is a molecular diagnostics company focused on cancer detection through innovative screening tests like Cologuard and Oncotype DX. Immuno-oncology companies face tailwinds from precision medicine advancements but also challenges like drug pricing scrutiny and competition from larger pharmaceutical companies. While Exact Sciences has shown strong sales growth, its operating margin has been consistently negative. The company’s Q4 earnings per share improved to -$0.06, exceeding analysts’ expectations.

Overall, Exact Sciences had a solid quarter with revenue beating estimates and improved EPS, but the market reacted negatively. Investors should consider the company’s valuation and business qualities before making an investment decision.



Read more at Stock Story: Exact Sciences’s (NASDAQ:EXAS) Q4: Beats On Revenue